BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 9844931)

  • 21. Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction.
    Tarusawa M; Yashima A; Endo M; Maesawa C
    Int J Hematol; 2002 Feb; 75(2):166-73. PubMed ID: 11939263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
    de Haas V; Breunis WB; Dee R; Verhagen OJ; Kroes W; van Wering ER; van Dongen JJ; van den Berg H; van der Schoot CE
    Br J Haematol; 2002 Jan; 116(1):87-93. PubMed ID: 11841400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
    Beishuizen A; Verhoeven MA; van Wering ER; Hählen K; Hooijkaas H; van Dongen JJ
    Blood; 1994 Apr; 83(8):2238-47. PubMed ID: 8161789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
    van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
    Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
    Jia YP; Liu GL; Zhang LP
    Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols].
    Yao L; Chen ZX; Cen JN; Liang JY; He J; Qi XF; Shen HJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):676-8. PubMed ID: 19176062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
    Liu JY; Li ZG; Gao C; Cui L; Wu MY
    Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes.
    Eckert C; Scrideli CA; Taube T; Songia S; Wellmann S; Manenti M; Seeger K; Biondi A; Cazzaniga G
    Leukemia; 2003 Dec; 17(12):2517-24. PubMed ID: 14562127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
    Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
    Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.
    Cazzaniga G; d'Aniello E; Corral L; Biondi A
    Best Pract Res Clin Haematol; 2002 Dec; 15(4):623-38. PubMed ID: 12617867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
    van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
    Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
    Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
    Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
    Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
    Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease.
    Peham M; Panzer S; Fasching K; Haas OA; Fischer S; Marschalek R; Gadner H; Panzer-Grümayer ER
    Br J Haematol; 2002 May; 117(2):315-21. PubMed ID: 11972513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.